Compare COPR & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COPR | ENTX |
|---|---|---|
| Founded | N/A | 2010 |
| Country | | Israel |
| Employees | 32 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.0M | 58.2M |
| IPO Year | N/A | 2015 |
| Metric | COPR | ENTX |
|---|---|---|
| Price | $2.21 | $2.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 34.2K | ★ 3.6M |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $42.86 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.16 | $0.91 |
| 52 Week High | $4.16 | $4.20 |
| Indicator | COPR | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 8.29 | 65.52 |
| Support Level | N/A | $1.16 |
| Resistance Level | $3.00 | $3.22 |
| Average True Range (ATR) | 0.31 | 0.32 |
| MACD | -0.07 | 0.14 |
| Stochastic Oscillator | 0.00 | 54.37 |
Idaho Copper Corp is a USA-based company focused on exploring and developing its copper-molybdenum-silver deposit in Idaho, known as the CuMo project. The CuMo project currently consists of several federal unpatented lode mining claims and various patented mining claims. The unpatented lode mining claims and patented claims are situated in an unorganized mining district, in Boise County, Idaho, spanning Sections in Township 7N and 8N, Range 5E and 6E, Boise Meridian.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.